KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) Leases (2019 - 2025)

Acadia Pharmaceuticals (ACAD) has 7 years of Leases data on record, last reported at $47.4 million in Q4 2025.

  • For Q4 2025, Leases rose 1.68% year-over-year to $47.4 million; the TTM value through Dec 2025 reached $47.4 million, up 1.68%, while the annual FY2025 figure was $47.4 million, 1.68% up from the prior year.
  • Leases reached $47.4 million in Q4 2025 per ACAD's latest filing, down from $49.7 million in the prior quarter.
  • Across five years, Leases topped out at $63.1 million in Q1 2021 and bottomed at $44.3 million in Q3 2024.
  • Average Leases over 5 years is $53.8 million, with a median of $53.3 million recorded in 2023.
  • Peak YoY movement for Leases: skyrocketed 678.82% in 2021, then fell 12.82% in 2024.
  • A 5-year view of Leases shows it stood at $58.3 million in 2021, then decreased by 4.63% to $55.6 million in 2022, then decreased by 6.69% to $51.9 million in 2023, then dropped by 10.19% to $46.6 million in 2024, then rose by 1.68% to $47.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $47.4 million in Q4 2025, $49.7 million in Q3 2025, and $51.0 million in Q2 2025.